{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:20:27Z","timestamp":1760145627946,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Albamunity (LHV)","award":["ANR-11-INBS-0008"],"award-info":[{"award-number":["ANR-11-INBS-0008"]}]},{"name":"Giving\/Grousbeck (Emilia Fazzalari and Wyc Grousbeck)","award":["ANR-11-INBS-0008"],"award-info":[{"award-number":["ANR-11-INBS-0008"]}]},{"name":"One Step Forward Education Foundation","award":["ANR-11-INBS-0008"],"award-info":[{"award-number":["ANR-11-INBS-0008"]}]},{"name":"Jewish Federation of Cleveland","award":["ANR-11-INBS-0008"],"award-info":[{"award-number":["ANR-11-INBS-0008"]}]},{"name":"The Tej Kohli Foundation","award":["ANR-11-INBS-0008"],"award-info":[{"award-number":["ANR-11-INBS-0008"]}]},{"name":"Programme Investissements d\u2019Avenir (PIA)","award":["ANR-11-INBS-0008"],"award-info":[{"award-number":["ANR-11-INBS-0008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>PARVAX is a genetic vaccine platform based on an adeno-associated vector that has demonstrated to elicit potent, durable, and protective immunity in nonhuman primates (NHPs) after a single dose. Here, we assessed vaccine immunogenicity following a PARVAX prime-boost regimen against SARS-CoV-2. In mice, a low-dose prime followed by a higher-dose boost elicited potent neutralizing antibody responses and distinct cross-reactivity profiles, depending on the antigen used in the booster vaccine. However, the potent neutralizing anti-vector antibody responses developed in mice limited the dose that could be administered as a prime. We further explored the re-administration efficacy in NHPs primed with a SARS-CoV-2 Delta vaccine and boosted with an Omicron BA.1 vaccine at week 15, after the primary response peak antibody levels were reached. The boost elicited an increase in antibodies against several Omicron variants, but no increase was detected in the antibody titers for other variants. The anti-vector responses were low and showed some increased subsequent boosts but generally declined over time. The potent prime vaccination limited the detection of the boosting effect, and therefore, the effect of anti-vector immunity was not fully elucidated. These data show that PARVAX can be effectively re-administered and induce a novel antigenic response.<\/jats:p>","DOI":"10.3390\/vaccines12080882","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T18:21:40Z","timestamp":1722882100000},"page":"882","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Boost and Increased Antibody Breadth Following a Second Dose of PARVAX for SARS-CoV-2 in Mice and Nonhuman Primates"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-5289","authenticated-orcid":false,"given":"Urja","family":"Bhatt","sequence":"first","affiliation":[{"name":"Grousbeck Gene Therapy Center, Ocular Genomics Institute and Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA"},{"name":"The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile","family":"Herate","sequence":"additional","affiliation":[{"name":"Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB\/IDMIT), Universit\u00e9 Paris-Saclay, Inserm, CEA, 92260 Fontenay-aux-Roses, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reynette","family":"Estelien","sequence":"additional","affiliation":[{"name":"Grousbeck Gene Therapy Center, Ocular Genomics Institute and Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA"},{"name":"The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6387-8481","authenticated-orcid":false,"given":"Francis","family":"Relouzat","sequence":"additional","affiliation":[{"name":"Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB\/IDMIT), Universit\u00e9 Paris-Saclay, Inserm, CEA, 92260 Fontenay-aux-Roses, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-6313","authenticated-orcid":false,"given":"Nathalie","family":"Dereuddre-Bosquet","sequence":"additional","affiliation":[{"name":"Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB\/IDMIT), Universit\u00e9 Paris-Saclay, Inserm, CEA, 92260 Fontenay-aux-Roses, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-9535","authenticated-orcid":false,"given":"Dawid","family":"Maciorowski","sequence":"additional","affiliation":[{"name":"Grousbeck Gene Therapy Center, Ocular Genomics Institute and Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA"},{"name":"The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-0172","authenticated-orcid":false,"given":"Cheikh","family":"Diop","sequence":"additional","affiliation":[{"name":"Grousbeck Gene Therapy Center, Ocular Genomics Institute and Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA"},{"name":"The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Couto","sequence":"additional","affiliation":[{"name":"Grousbeck Gene Therapy Center, Ocular Genomics Institute and Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA"},{"name":"The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian","family":"Staiti","sequence":"additional","affiliation":[{"name":"Grousbeck Gene Therapy Center, Ocular Genomics Institute and Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA"},{"name":"The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8468-0263","authenticated-orcid":false,"given":"Mariangela","family":"Cavarelli","sequence":"additional","affiliation":[{"name":"Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB\/IDMIT), Universit\u00e9 Paris-Saclay, Inserm, CEA, 92260 Fontenay-aux-Roses, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-9277","authenticated-orcid":false,"given":"La\u00ebtitia","family":"Bossevot","sequence":"additional","affiliation":[{"name":"Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB\/IDMIT), Universit\u00e9 Paris-Saclay, Inserm, CEA, 92260 Fontenay-aux-Roses, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Sconosciuti","sequence":"additional","affiliation":[{"name":"Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB\/IDMIT), Universit\u00e9 Paris-Saclay, Inserm, CEA, 92260 Fontenay-aux-Roses, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-1941","authenticated-orcid":false,"given":"Page","family":"Bouchard","sequence":"additional","affiliation":[{"name":"Ciendias Bio, Weston, MA 02493, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4928-4484","authenticated-orcid":false,"given":"Roger","family":"Le Grand","sequence":"additional","affiliation":[{"name":"Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB\/IDMIT), Universit\u00e9 Paris-Saclay, Inserm, CEA, 92260 Fontenay-aux-Roses, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-4924","authenticated-orcid":false,"given":"Luk H.","family":"Vandenberghe","sequence":"additional","affiliation":[{"name":"Grousbeck Gene Therapy Center, Ocular Genomics Institute and Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA"},{"name":"The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"},{"name":"Ciendias Bio, Weston, MA 02493, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-4695","authenticated-orcid":false,"given":"Nerea","family":"Zabaleta","sequence":"additional","affiliation":[{"name":"Grousbeck Gene Therapy Center, Ocular Genomics Institute and Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA"},{"name":"The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.ymthe.2022.05.007","article-title":"Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques","volume":"30","author":"Zabaleta","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.chom.2021.08.002","article-title":"An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates","volume":"29","author":"Zabaleta","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.4049\/jimmunol.0803965","article-title":"Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins","volume":"182","author":"Mays","year":"2009","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2013.134","article-title":"AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells","volume":"22","author":"Mays","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.53854\/liim-2903-3","article-title":"Review of COVID-19 viral vector-based vaccines and COVID-19 variants","volume":"29","author":"Vanaparthy","year":"2021","journal-title":"Infez. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiac142","article-title":"Impact of Preexisting Anti\u2013Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine","volume":"226","author":"Sadoff","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41541-022-00566-x","article-title":"Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination","volume":"7","author":"Byazrova","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1089\/hum.2010.055","article-title":"Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale","volume":"21","author":"Lock","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-4939-9139-6_4","article-title":"Quantitative and Digital Droplet-Based AAV Genome Titration","volume":"1950","author":"Sanmiguel","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104572","DOI":"10.1016\/j.jcv.2020.104572","article-title":"Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2","volume":"130","author":"Johnson","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eadj0070","DOI":"10.1126\/science.adj0070","article-title":"Mapping SARS-CoV-2 antigenic relationships and serological responses","volume":"382","author":"Wilks","year":"2023","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eabq4450","DOI":"10.1126\/sciimmunol.abq4450","article-title":"Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct","volume":"7","author":"Mykytyn","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: A mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2021.19499","article-title":"Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity","volume":"326","author":"Tenforde","year":"2021","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.3346\/jkms.2023.38.e396","article-title":"Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023","volume":"38","author":"Kim","year":"2023","journal-title":"J. Korean Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","article-title":"Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5 ch and AAV1","volume":"25","author":"Majowicz","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Calcedo, R., and Wilson, J.M. (2013). Humoral Immune Response to AAV. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00341"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1016\/j.vaccine.2016.10.053","article-title":"Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques","volume":"34","author":"Greig","year":"2016","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/8\/882\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:29:21Z","timestamp":1760110161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/8\/882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["vaccines12080882"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12080882","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,8,2]]}}}